Positron emission tomography of the heart.

Mathis Ca , Derenzo Se , Budinger Tf , Knittel B
The Physiologist 26 ( 1) 31

11
1983
Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.

Ruszkiewicz J , Thomas Sm , Mason Ns , Mathis Ca
American journal of nuclear medicine and molecular imaging 3 ( 1) 16 -31

4
2013
(R)-(−)-[77Br]4-Bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes

SJ Peroutka , A Hamik , MA Harrington , AJ Hoffman
Molecular Pharmacology 34 ( 4) 537 -542

18
1988
A 122Xe−122I generator for remote radio-iodinations

T. Sargent , M. C. Lagunas-Solar , Y. Yano , L. J. Harris
The International Journal of Applied Radiation and Isotopes 37 ( 3) 258 -260

8
1986
Gender-specific aging reductions in [11C-carbonyl] WAY100635 binding: Not an effect of atrophy

V. L. Villemagne , B. J. Lopresti , C. C. Meltzer , S. T. DeKosky
NeuroImage 11

1
2000
In vivo evaluation and imaging of a lipophilic derivative of Congo red for amyloid assessments

M. L. Debnath , B. T. Hyman , C. A. Mathis , Y. Wang
Journal of Nuclear Medicine 42(5 Supplement) 252

5
2001
Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern?

J. Sojkova , L. Beason-Held , Y. Zhou , Y. An
The Journal of Nuclear Medicine 49 ( 9) 1465 -1471

56
2008
Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia

B. E. Snitz , L. A. Weissfeld , O. L. Lopez , L. H. Kuller
Neurology 80 ( 15) 1378 -1384

57
2013
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

W. E. Klunk , C. A. Mathis , J. C. Price , B. J. Lopresti
Brain 129 ( 11) 2805 -2807

48
2006
Spatial patterns of brain amyloid-β burden and atrophy rate associations in mild cognitive impairment

D. Tosun , N. Schuff , C. A. Mathis , W. Jagust
Brain 134 ( 4) 1077 -1088

81
2011
β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

K. E. Pike , G. Savage , V. L. Villemagne , S. Ng
Brain 130 ( 11) 2837 -2844

916
2007
POSITRON EMISSION TOMOGRAPHY AND PLATELET LABELLING IN THE STUDY OF ATHEROSCLEROSIS

Y. Yano , K. H. Brenna , M. Singh , J. A. Twitchell
Clinical Nuclear Medicine 9 46

1984
Relationships between biomarkers in aging and dementia.

W. J. Jagust , S. M. Landau , L. M. Shaw , J. Q. Trojanowski
Neurology 73 ( 15) 1193 -1199

382
2009
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB

S. M. Resnick , J. Sojkova , Y. Zhou , Y. An
Neurology 74 ( 10) 807 -815

293
2010
Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease

M. D. Ikonomovic , W. E. Klunk , E. E. Abrahamson , J. Wuu
Neurology 77 ( 1) 39 -47

57
2011
Lipophilic 11C‐labelled thioflavin‐T analogues for imaging amyloid plaques in alzheimer's disease

C. A. Mathis , D. P. Holt , Y. Wang , G-F. Huang
Journal of Labelled Compounds and Radiopharmaceuticals 44

19
2001
9
2001
Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve

A. D. Cohen , J. C. Price , L. A. Weissfeld , J. James
The Journal of Neuroscience 29 ( 47) 14770 -14778

179
2009
Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PET.

C. M. Laymon , N. S. Mason , W. G. Frankle , J. P. Carney
The Journal of Nuclear Medicine 50 ( 5) 814 -817

15
2009
Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements

R. L. McNamee , S.-H. Yee , J. C. Price , W. E. Klunk
The Journal of Nuclear Medicine 50 ( 3) 348 -355

84
2009